Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airf...

Source: Respiratory Research - December 11, 2017 Category: Respiratory Medicine Authors: Leif Bjermer, Job F. M. van Boven, Madlaina Costa-Scharplatz, Dorothy L. Keininger, Florian S. Gutzwiller, Karin Lisspers, Ronan Mahon, Petter Olsson and Nicolas Roche Tags: Research Source Type: research